Ginger supplements and HbA1c in type 2 diabetes: what the 2024 review shows

The main takeaway is that the available studies have not provided statistical proof of an overall effect of isolated ginger on fasting glycemia and HbA1c. Simply put, when aggregating the data from the five studies, the difference between those who took ginger and those who received the control was not consistent enough to reasonably rule out chance.

The doses ranged from 1.2 to 2 g per day, and the duration lasted between four and twelve weeks. Two individual studies reported a significant decrease in fasting glycemia, but this was not enough to make the synthesis result significant. The data suggests variability in response, not an absolute absence of effect. However, it does not prove that ginger lowers glycemia in all people or that it reduces diabetes complications. Therefore, to interpret this, one must consider the clinical and methodological context.

This publication is relevant because it distinguishes the impression created by certain positive results from the conclusion that can be drawn when multiple trials are evaluated together. An improvement observed in a small study may be real, coincidental, or linked to the specific characteristics of the participants, the diet, concomitant treatments, or the product used.

The review therefore distinguishes a possible biological signal from clinical evidence sufficient to claim a consistent benefit. For a person with type 2 diabetes, glycemia and HbA1c remain important indicators, but any change in them following supplementation does not automatically equate to a lower probability of complications. The 2024 study by Schumacher and colleagues supports the research interest in ginger, but does not change its role: a support to be studied, not a substitute for prescribed therapies.

The main limitation is the small number of available trials. Five studies do not allow us to understand precisely which individuals might respond best, which preparation is most suitable, or whether the effect persists beyond a few weeks. The capsules were not all identical, and the quantity of active ginger compounds is not uniformly standardized.

Differences in dosage, duration, and participants make direct comparison difficult. Furthermore, the research measured laboratory markers rather than clinical events such as hospitalizations, microvascular complications, or quality of life. It does not demonstrate a causal effect on diabetes complications, does not identify a one-size-fits-all dose, and does not allow for the replacement of medications, personalized nutrition, physical activity, or medical monitoring. The null result of the synthesis does not even prove that every formulation is ineffective: it indicates that the evidence examined was not uniform enough for a solid positive conclusion.

An updated meta-analysis of 13 randomized trials found average reductions in fasting glycemia and HbA1c, but with very high heterogeneity: I² of 86.39% and 92.09%. The I² indicates how much of the differences between scientific papers appears to depend on real variations between studies rather than chance alone. The authors also judged the effects to be of limited clinical importance. This passage confirms, above all, the caution of the Schumacher study: a favorable average signal exists, but it is not uniform [1].

A previous meta-analysis of ten randomized trials, conducted exclusively in type 2 diabetes, observed an average reduction in fasting glycemia of 18.81 mg/dL and HbA1c of 0.57 percentage points. Here, too, however, heterogeneity was high, with I²=77.4% respectively. The relationship with the 2024 review is direct: it supports the hypothesis of a possible effect, but shows that estimates change significantly depending on the studies included and the analysis methods [2].

A third meta-analysis included nine trials in different populations, four of which involved type 2 diabetes. It reported an average variation in fasting glycemia of −1.35 mg/dL and HbA1c of −1.01, with confidence intervals that did not cross zero. Since it did not exclusively concern type 2 diabetes, the confirmation is indirect. Furthermore, sample sizes ranged from 10 to 88 participants and the clinical context was heterogeneous [3].

Some publications reach more favorable conclusions compared to the overall null result of the 2024 review. Daily and colleagues pooled five randomized trials and found a significant decrease in fasting glycemia and HbA1c. However, they did not observe a statistically significant reduction in fasting insulin or HOMA-IR, an index that estimates insulin resistance. This difference suggests that any variations in glycemia alone do not identify the mechanism involved [4].

In a double-blind, placebo-controlled trial, Arablou and colleagues involved 70 people with type 2 diabetes: 1,600 mg per day of ginger for 12 weeks was associated with significant reductions in fasting glycemia, HbA1c, insulin, and HOMA compared to the placebo. This finding contrasts with the null synthesis by Schumacher, but it does not invalidate it: it is a single study, of short duration, with a specific dose and population. In the same trial, no significant differences emerged for HDL cholesterol, LDL cholesterol, and TNF-alpha, an inflammatory marker [5].